Core Viewpoint - COSCIENS Biopharma Inc. has initiated its Phase 2a clinical efficacy study for its avenanthramides product, aimed at managing inflammation-related conditions, following a successful Phase 1 trial that demonstrated a favorable safety profile [1][4][5]. Group 1: Clinical Study Details - The Phase 1-2a clinical trial, named the AvenActive study, began in November 2023 and involved 72 healthy subjects, with no significant adverse events reported [3][8]. - The Phase 2a study will enroll 20 patients with mild to moderate inflammation, testing doses of 480 mg and 960 mg per day [4][5]. - Initial dosing for the Phase 2a study is expected to occur on March 14, 2025, at the Montreal Heart Institute [4][8]. Group 2: Product Information - Avenanthramides are di-phenolic compounds found in oats, known for their antioxidant and anti-inflammatory properties [2]. - The study will assess inflammatory biomarkers in blood, focusing on cytokines, chemokines, and high-sensitivity C-reactive protein [5]. Group 3: Company Strategy and Market Potential - The successful completion of the Phase 1 study is viewed as a critical milestone, positioning the company for potential out-licensing and commercialization opportunities [6]. - The company aims to become a global leader in natural-based health and wellness products, with avenanthramides seen as a transformative product [6][10].
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product